Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 462

Sort by

Sort Order Select

Journal Articles

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Judith Trotman, Katherine Rankin, Ibrahim Tohidi-Esfahani, Alessandra Tedeschi, Constantine S. Tam, Christian Buske, Roger G Owen, Veronique LeBlond, Meletios A. Dimopoulos, Peter Smallwood, Heather Allewelt, Wai Y Chan, Radha Prathikanti, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2024-200334

Published: 2024

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Panagiotis Malandrakis, Pantelis Rousakis, Chrysanthi Panteli, Evangelos Eleutherakis-Papaiakovou, Vasiliki Spiliopoulou, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Nikolaos Kanellias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios A. Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 490.

https://doi.org/10.1182/blood-2024-194090

Published: 2024

Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Blood (2024) 144 (Supplement 1): 859.

https://doi.org/10.1182/blood-2024-200604

Published: 2024

Journal Articles

Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, Panagiotis Malandrakis, Efstathios Kastritis, Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 4696.

https://doi.org/10.1182/blood-2024-194398

Published: 2024

Journal Articles

Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

Maria Gavriatopoulou, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Maria Douka, Vasiliki Spiliopoulou, Charalampos Filippatos, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Lia-Angela Moulopoulos

Blood (2024) 144 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2024-209637

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Blood (2024) 144 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2024-198408

Published: 2024

Journal Articles

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Shirley D'Sa, Meletios A. Dimopoulos, Wojciech Jurczak, Paula Marlton, Stephen P. Mulligan, Bjorn E Wahlin, Magdalena Sobieraj-Teague, Andrew W. Roberts, Constantine S. Tam, Jorge J. Castillo, Heather Allewelt, Radha Prathikanti, Wai Y Chan, Tian Tian, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2024-199276

Published: 2024

Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Blood (2024) 144 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2024-199282

Published: 2024

Journal Articles

Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

Noemi Puig, Panagiotis Malandrakis, Cristina Agullo, Sergio Castro, Teresa Contreras, Veronica Gonzalez-Calle, Beatriz Rey-Búa, Borja Puertas Martínez, Evangelos Terpos, Meletios A. Dimopoulos, Maria- Victoria Mateos, Efstathios Kastritis

Blood (2024) 144 (Supplement 1): 4694.

https://doi.org/10.1182/blood-2024-209661

Published: 2024

Journal Articles

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Blood (2024) 144 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2024-200038

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 4.

https://doi.org/10.1182/blood-2023-177546

Published: 2023

Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2023-174294

Published: 2023

Journal Articles

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Blood (2023) 142 (Supplement 1): 4734.

https://doi.org/10.1182/blood-2023-179416

Published: 2023

Journal Articles

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Stavros Gkolfinopoulos, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2023-173074

Published: 2023

Journal Articles

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Argiris Symeonidis, Anastasia Pouli, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Ioannis Ninos, Sosana Delimpasi, Eleftheria Hatzimichael, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6728.

https://doi.org/10.1182/blood-2023-173170

Published: 2023

NARROW

Long-Term Impact of Dose Interruptions (DIs) of Bruton Tyrosine Kinase Inhibitors (BTKis) on Change in IgM Levels and Clinical Outcomes in Waldenström Macroglobulinemia (WM)

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Sequential Whole Body Low Dose CTs in Patients with Smoldering Multiple Myeloma Identify Early Progression and May Improve Patient Outcomes

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Measurable Residual Disease and Peripheral Residual Disease to Assess Treatment Response in Real-World Patients with Newly Diagnosed Multiple Myeloma

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only